Company profile
RIGEL PHARMACEUTICALS INC
NASDAQ:RIGLBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| GAVRETO | approved | — | 1 | approved |
| REZLIDHIA | approved | — | 2 | approved |
| TAVALISSE | approved | — | 11 | approved |
| VEPPANU | approved | — | 19 | approved |
| R-343 | phase2 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (26)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00115089 | phase2 | completed | 2005-07-01 | — | Rigel Pharmaceuticals | 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis |
| NCT02076412 | phase3 | completed | 2015-01-01 | 2016-08-01 | Rigel Pharmaceuticals | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| NCT02076399 | phase3 | completed | 2014-07-14 | 2016-04-21 | Rigel Pharmaceuticals | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| NCT04138927 | phase3 | enrolling_by_invitation | 2019-10-30 | 2024-04-01 | Rigel Pharmaceuticals | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia |
| NCT03764618 | phase3 | completed | 2019-04-24 | 2022-04-11 | Rigel Pharmaceuticals | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA |
FDA applications (4)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 219835 | 2026-05-01 | NDA | RIGEL PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 215814 | 2022-12-01 | NDA | RIGEL PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 213721 | 2020-09-04 | NDA | RIGEL PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 209299 | 2018-04-17 | NDA | RIGEL PHARMACEUTICALS INC | |||||
Loading… | ||||||||